VSC On Other Exchanges
Symbol
Exchange
Xetra
OTC US

4sc ag (VSC) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for 4SC AG (VSC)
\

Related News

No related news articles were found.

4sc ag (VSC) Related Businessweek News

No Related Businessweek News Found

4sc ag (VSC) Details

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development. The company’s products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma and biliary tract cancer; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. Its product in preclinical stage includes 4SC-208, a small molecule targeting two kinases crucial for Hedgehog/GLI signaling. The company also out-licenses its products to pharma and biotech companies for the treatment of cancer. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.

32 Employees
Last Reported Date: 03/18/19
Founded in 1997

4sc ag (VSC) Top Compensated Officers

Chairman of Management Board, CEO & MD
Total Annual Compensation: €669.0K
Compensation as of Fiscal Year 2018.
4sc ag
4SC AG Presents at BioEquity Europe 2019, May-20-2019 04:30 PM

4SC AG Presents at BioEquity Europe 2019, May-20-2019 04:30 PM. Venue: Crowne Plaza Barcelona Fira Center Hotel, Avenida Rius I Taulet, 1-3, Barcelona, Spain. Speakers: Dominique Doyen, Director, Business Development.

4SC AG Presents at 2019 American Association for Cancer Research (AACR) Annual Meeting, Mar-29-2019

4SC AG Presents at 2019 American Association for Cancer Research (AACR) Annual Meeting, Mar-29-2019 . Venue: Georgia World Congress Center, Atlanta, Georgia, United States.

Dynavax's SD-101 and 4SC's Domatinostat Demonstrate Synergy and Induce Systemic Anti-tumor Response in Preclinical Models

Dynavax Technologies Corporation and 4SC AG announced the combination of 4SC's orally available class I selective HDAC inhibitor domatinostat (4SC-202) with Dynavax's intratumoral TLR9 agonist SD-101 induced a systemic anti-tumoral immune response in tumor mouse models, resulting in the significant decrease in tumor size of both target tumors and distant site metastases. Combination of SD-101 with domatinostat showed better results than combinations of SD-101 with competing HDAC inhibitors. The triple combination of both compounds with PD-1 blockade (checkpoint inhibition) demonstrated even higher efficacy. SD-101 is a TLR9 agonist, which was specifically developed for cancer based upon its ability to stimulate both IFN-? production and the maturation of plasmacytoid dendritic cells into tumor antigen presenting cells. This results in increased activation and proliferation of tumor-specific CD8+ T cells which attack distant site non-injected tumors. Domatinostat, acting via epigenetic regulation, renders tumor cells more visible to the immune system and promotes a general immune response against tumor tissue as well as infiltration of T cells into the tumor tissue. Preclinical data demonstrate that the combination of intra-tumoral SD-101 and systemic domatinostat strongly synergize to induce substantial regression of the primary (injected) tumor, as well as distant site non-injected tumors, including lung metastases. Checkpoint inhibitors, such as anti-PD-1 antibodies further boost the anti-tumor T-cell response, leading to rejection in mice with high metastatic burden. These data indicate that the combination of these three different treatment classes result in induction of a more potent tumor-specific immune response and better recognition and elimination of tumors by immune cells, especially in cancer patients refractory to anti-PD-1 treatment.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

VSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSC.
View Industry Companies
 

Industry Analysis

VSC

Industry Average

Valuation VSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.1x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 4SC AG, please visit www.4sc.de. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.